ClinicalTrials.gg

Cardiomyopathy, Hypertrophic clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 364 studies for Cardiomyopathy, Hypertrophic across more than 10 countries. 117 are recruiting or about to start. 304 of them are mainly about Cardiomyopathy, Hypertrophic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Completed
138
Recruiting
81
Status unknown
46
Active, not recruiting
40
Not yet recruiting
25
Terminated
17

Phase

Phase 2
45
Phase 3
29
Phase 1
20
Phase 4
16
Early Phase 1
2

Where

United States
125
China
71
United Kingdom
52
France
33
Italy
31
Germany
29

Who develops what

Add Cardiomyopathy, Hypertrophic to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 7 with this as their studies’ main aim; 4 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Bayer, Bristol-Myers Squibb and Jiangsu HengRui Medicine here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MetoprololRecent, repeated
Evidence
  • NCT07755904 · Braveheart Bio, Inc. · Phase 3 · live · comparator · “Metoprolol” · registered Aug 2026
  • NCT05767346 · Cytokinetics · Phase 3 · comparator · “Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)” · registered Mar 2023
AstraZeneca16% of its industry studiesUS: off-patent, 25 generics marketed22 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
BHB-1893☆ Track1 live phase-3 study: NCT07755904Braveheart Bio, Inc.
mavacamtenApproved: US 2022 · EU 2023☆ Track2 live phase-3 studies: NCT07940777, NCT06253221Bristol-Myers Squibb
aficamtenApproved: US 2025 · EU 2026☆ Track1 live phase-3 study: NCT07023341Bayer
HRS-1893☆ Track1 live phase-3 study: NCT07021976Jiangsu HengRui Medicine Co., Ltd.

The 4 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.ninerafaxstat · Imbria Pharmaceuticals, Inc. · Phase 2 main aimNCT07023614 A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy — primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) · 165 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cardiomyopathy, Hypertrophic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SGLT2 inhibitors 2 open · Calcium channel blockers 1 open · Beta blockers 1 open · Angiotensin receptor blockers (ARBs) 7

Coming up

40studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger. 21 (26%) take children under 18. 1 (1%) are for women only and 1 (1%) for men only; 13 (16%) take healthy volunteers.

Recruiting studies that take each age, of 81
AgeWomenMen
1015 (19%)16 (20%)
1872 (89%)72 (89%)
3076 (94%)76 (94%)
4078 (96%)78 (96%)
5079 (98%)79 (98%)
6579 (98%)79 (98%)
7576 (94%)76 (94%)
8564 (79%)64 (79%)

Across all 364 studies, recruiting or not: 22% stop at 75 or younger and 13% at 65; 24% take children; <1% are for women only and 1% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cardiomyopathy, Hypertrophic studies take

Of 20 phase 2 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 36 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 15 mo3–12 · 12 studies——
Phase 236 mo21–43 · 20 studies——
Phase 321 mo19–36 · 15 studies——
Interventional, no phase52 mo26–60 · 52 studies—43 mo26–60 · 47 studies
Observational85 mo43–… · 82 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 364. Browse all 364 → or search them.